胎儿生长受限合并脐动脉多普勒异常时母体血浆可溶性神经纤毛蛋白-1下调:一项先导研究
前瞻性病例对照先导研究纳入40例单胎妊娠(20例胎儿生长受限、20例无并发症对照),于2015年1月至2017年5月在学术围产中心随访。母体血浆可溶性神经纤毛蛋白-1在胎儿生长受限组显著低于正常胎儿生长组(137.4±44.8 pg/mL vs 166.7±36.9 pg/mL,P=0.03),且仅在脐动脉多普勒异常的生长受限亚组中下调。
要点
- 胎儿生长受限合并脐动脉收缩/舒张比值升高或舒张末期血流缺失/反向时,母体血浆可溶性神经纤毛蛋白-1下调。
- 脐动脉多普勒正常的生长受限与对照组可溶性神经纤毛蛋白-1无显著差异,提示可能为小于胎龄儿而非真正胎儿生长受限。
- 可溶性神经纤毛蛋白-1可能参与调节胎儿生长,并可能作为胎儿生长受限的生物标志物。
诊断标准与关键数值
- 胎儿生长受限定义为超声估计胎儿体重小于同孕龄第10百分位。
- 胎儿生长受限组母体血浆可溶性神经纤毛蛋白-1为137.4±44.8 pg/mL,正常胎儿生长组为166.7±36.9 pg/mL,胎儿生长受限组显著降低(P=0.03)。
- 对照组与脐动脉多普勒正常的胎儿生长受限组之间可溶性神经纤毛蛋白-1浓度无显著差异。
- 脐动脉收缩/舒张比值升高的胎儿生长受限组可溶性神经纤毛蛋白-1较脐动脉多普勒正常的胎儿生长受限组下调(P=0.023)。
- 脐动脉舒张末期血流缺失或反向的胎儿生长受限组可溶性神经纤毛蛋白-1较脐动脉多普勒正常的胎儿生长受限组下调(P=0.005)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: Placental expression of neuropilin-1 (NRP1), a proangiogenic member of the vascular endothelial growth factor receptor family involved in sprouting angiogenesis, was recently discovered to be downregulated in pregnancies with fetal growth restriction (FGR) and abnormal umbilical artery (UA) Doppler. Soluble NRP1 (sNRP1) is an antagonist to NRP1; however, little is known about its role in normal and FGR pregnancies. This study tested the hypotheses that, first, sNRP1 would be detectable in maternal circulation and, second, its concentration would be upregulated in FGR pregnancies compared to those with normal fetal growth and this would correlate with the severity of the disease as assessed by UA Doppler.
METHODS: This was a prospective case-control pilot study of 40 singleton pregnancies (20 FGR cases and 20 uncomplicated controls) between 24 + 0 and 40 + 0 weeks' gestation followed in an academic perinatal center from January 2015 to May 2017. FGR was defined as an ultrasound-estimated fetal weight < 10th percentile for gestational age. The control group was matched to the FGR group for maternal age and gestational age at assessment. Fetal ultrasound biometry and UA Doppler were performed using standard protocols. Maternal plasma sNRP1 measurements were performed using a commercially available ELISA.
RESULTS: Contrary to the study hypothesis, maternal plasma sNRP1 levels were significantly decreased in FGR pregnancies as compared to those with normal fetal growth (137.4 ± 44.8 pg/mL vs 166.7 ± 36.9 pg/mL; P = 0.03). However, there was no significant difference in sNRP1 concentration between the control group and FGR pregnancies that had normal UA Doppler. Plasma sNRP1 was downregulated in FGR pregnancies with elevated UA systolic/diastolic ratio (P = 0.023) and those with UA absent or reversed end-diastolic flow (P = 0.005) in comparison to FGR pregnancies with normal UA Doppler. This suggests that biometrically small fetuses without hemodynamic compromise are small-for-gestational age rather than FGR.
CONCLUSIONS: This study demonstrated a significant decrease in maternal plasma sNRP1 concentration in growth-restricted pregnancies with fetoplacental circulatory compromise. These findings suggest a possible role of sNRP1 in modulating fetal growth and its potential as a biomarker for FGR. © 2021 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Porter B, Maulik D, Babbar S, et al. Maternal plasma soluble neuropilin-1 is downregulated in fetal growth restriction complicated by abnormal umbilical artery Doppler: a pilot study. Ultrasound Obstet Gynecol. 2021. PMID: 33533520. doi:10.1002/uog.23605
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。